Alzamend Neuro, Inc. (ALZN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
3500 Lenox Road NE
Atlanta, GA 30326
United States of America (the)
Phone
844 722 6333
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
June 15, 2021
| Name | Title | Pay | Year Born |
| Stephan Jackman | Chief Executive Officer & Director | 468,288 | 1977 |
| Milton Charles Ault | Founder & Vice Chairman | 25,000 | 1970 |
| Henry C. W. Nisser | Executive Vice President, General Counsel & Director | 50,000 | 1970 |
| David J. Katzoff | Chief Financial Officer | 150,000 | 1963 |
| Kenneth S. Cragun | Senior Vice President of Finance | 0 | 1961 |
Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical firm dedicated to advancing therapeutic solutions for neurodegenerative and psychiatric illnesses. Its development pipeline features two key candidates. AL001, currently in Phase II clinical trials, administers a proprietary blend of lithium, proline, and salicylate. This compound is designed to address a broad spectrum of conditions such as Alzheimer's, bipolar disorder, post-traumatic stress disorder (PTSD), major depressive disorder (MDD), and other neurodegenerative or psychiatric conditions. Also in its portfolio is AL002, which has successfully completed its preclinical phase. AL002 represents a cell-based therapeutic vaccine strategy, employing mutant-peptide sensitized cells to restore and enhance a patient's immune system in its fight against Alzheimer's disease. Incorporated in 2016, Alzamend Neuro, Inc. maintains its headquarters in Atlanta, Georgia.